Thermoresponsive PPCN Hydrogels for Injectable Bone Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current materials for bone repair are primarily focused on structural strength rather than inducing bone formation, and they fail to interact effectively with the cellular environment or facilitate localized drug delivery, especially in minimally invasive procedures for unique fracture sites and bone diseases.
Innovation Solution
Injectable, thermoresponsive hydrogels based on PPCN (poly(polyethylene glycol citrate-co-N-isopropylacrylamide) that are liquid at room temperature and gel at body temperature, incorporating bioactive agents like β-glycerophosphate, cyclic Arg-Gly-Asp peptides, and metal ions for controlled release and osteoinductive properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If hard filler pastes like methyl methacrylate or calcium phosphate are used for bone repair, then material strength is improved, but the ability to induce bone formation and interact with cellular environment deteriorates
Solution Approach 1:
The patent uses composite hydrogel materials combining poly(ethylene glycol) citrate, N-isopropylacrylamide, and bioactive agents like β-glycerophosphate and cRGD peptides. This composite approach provides both structural support and biological functionality, resolving the contradiction between strength and bone-forming capability by integrating multiple material properties into a single system.
Solution Approach 2:
The hydrogel undergoes thermoresponsive parameter changes, transitioning from liquid at room temperature to gel at body temperature. This parameter change enables the material to be injectable during surgery while providing structural support afterward, and the chemical composition can be modified to control degradation rate and drug release kinetics, adapting the material properties to match healing progression.
2Ease of operation
If minimally invasive procedures are used for bone repair, then patient trauma and recovery time are reduced, but the ability to conform to unique fracture sites and deliver localized therapy deteriorates
Solution Approach 1:
The hydrogel is delivered in liquid form through injection (hydraulic delivery), enabling minimally invasive administration. Once injected into the fracture site, the material undergoes sol-gel transition, transforming from fluid to solid state to conform precisely to the irregular geometry of the fracture cavity, thus achieving both easy delivery and site-specific adaptation.
Solution Approach 2:
The material exhibits dynamic properties by changing its physical state from liquid to gel in response to temperature changes. This dynamic transformation allows the material to adapt its form factor after delivery, filling complex fracture geometries that static materials cannot accommodate, while maintaining the benefits of minimally invasive injection.
3Adaptability or versatility
If bioactive agents are incorporated into hydrogels for controlled release, then localized drug delivery and bone formation are improved, but material complexity and manufacturing difficulty increase
Solution Approach 1:
The patent combines the structural polymer matrix (poly(ethylene glycol) citrate-co-N-isopropylacrylamide) with bioactive agents (β-glycerophosphate, cRGD peptides, strontium ions) into a single integrated hydrogel system. The bioactive components are incorporated during polymerization, merging the structural and therapeutic functions into one material rather than requiring separate delivery systems.
Solution Approach 2:
The hydrogel platform serves multiple functions simultaneously: providing structural support, enabling controlled drug release, promoting bone formation through osteoinductive agents, and offering thermoresponsive delivery. This multi-functional design achieves localized therapy without proportionally increasing complexity, as all functions are integrated into a single material system.
4Ease of operation
If thermoresponsive hydrogels are used that gel at body temperature, then injectability and controlled release are improved, but the complexity of controlling gelation and maintaining stability deteriorates
Solution Approach 1:
The hydrogel utilizes the phase transition of N-isopropylacrylamide, which exhibits a lower critical solution temperature (LCST) around body temperature. Below this temperature, the polymer chains are hydrophilic and soluble; above it, they become hydrophobic and aggregate to form gel. This inherent phase transition behavior provides automatic temperature-responsive gelation without requiring complex external control mechanisms.
Solution Approach 2:
The hydrogel system is self-regulating through its thermoresponsive properties. Upon injection into the body, the material automatically senses the temperature increase from room temperature to body temperature and triggers gelation autonomously. This self-service gelation mechanism eliminates the need for external triggers or complex control systems, reducing operational complexity despite the sophisticated temperature-responsive behavior.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PPCN-based hydrogels demonstrate thermoresponsive behavior, promoting bone formation and repair by inducing stem cells to become bone cells, facilitating controlled drug delivery, and showing significant mineralization and osteocalcin expression, while ensuring biocompatibility and localized strontium distribution.
Implementation Method 1
Injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release
Implementation Method 2
PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto
Data Source
AI summary
Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.